significant parametric pairwise t-test (p£0.05) and ii) area under the receiver-operator characteristic curve (AUROC !0.59) were selected for inclusion in a logistic regression model. Results The biomarkers that met criteria and were taken forward for further analysis are shown in Table 1 . Of these CC16, CRP, MMP8 and NGAL combined had an AUROC 0.82 (95% confidence interval 0.74 to 0.90). The Youden's index gave a sensitivity and specificity of 78% and 82% respectively. Conclusion COPD exacerbations can be identified by urinary biomarkers. The biomarker panel requires further validation in a prospective longitudinal study.
Background There is evidence that acute exacerbations of COPD (AECOPD) may be stratified by peripheral blood eosinophil count and that this may allow identification of a pathologically distinct phenotype with clinical value. We have compared lung function measures between patients with eosinophilic and non-eosinophilic AECOPD. Methods All admissions to an inner London teaching hospital with AECOPD were recorded between 2004 and 2012. The eosinophilic phenotype is defined as a first blood count within 24 hours of admission showing peripheral blood eosinophil count ³ 2% of white blood cells. The first lung function test recorded, performed in a dedicated-laboratory between admissions, were used in analysis. We used non-parametric statistics (Mann-Witney U) for univariate comparisons, and linear regression for multivariate analyses.
Results There were 2793 admissions with AECOPD recorded, we used only first admissions (1, 279 FEV1% predicted (p<0.001) . Figure 1 -A comparison of D L CO percent predicted measured in stable state, in patients with eosinophilic vs. non-eosinophilic AECOPD admissions.
Abstract P186 Figure 1 Discussion In this cohort, patients admitted to hospital with acute exacerbations of COPD associated with an eosinophilic phenotype had a higher FEV1 and higher DLCO% predicted. A lower DLCO is more associated with an "emphysematous" than "bronchial" form of COPD. Our Results suggest that the eosinophilic phenotype of AECOPD may be associated with less alveolar and pulmonary capillary damage. Background Patients presenting with an acute exacerbation of COPD (AECOPD) and a peripheral blood eosinophil count!=2% of the total white cell count have a better response to oral cortico-steroids, suggesting that stratification by this biomarker identifies a pathologically distinct phenotype
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